Nexthera Capital LP lowered its stake in Minerva Neurosciences, Inc (NASDAQ:NERV) by 24.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 575,000 shares of the biopharmaceutical company’s stock after selling 182,200 shares during the quarter. Minerva Neurosciences accounts for about 2.2% of Nexthera Capital LP’s portfolio, making the stock its 16th biggest holding. Nexthera Capital LP owned 1.35% of Minerva Neurosciences worth $5,089,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. State of Wisconsin Investment Board purchased a new position in shares of Minerva Neurosciences during the 2nd quarter worth $159,000. Vanguard Group Inc. raised its holdings in Minerva Neurosciences by 13.4% in the 1st quarter. Vanguard Group Inc. now owns 939,297 shares of the biopharmaceutical company’s stock valued at $7,608,000 after buying an additional 110,876 shares during the period. Laurion Capital Management LP purchased a new stake in Minerva Neurosciences in the 2nd quarter valued at about $326,000. ClariVest Asset Management LLC raised its holdings in Minerva Neurosciences by 1.0% in the 1st quarter. ClariVest Asset Management LLC now owns 29,200 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 300 shares during the period. Finally, Rhumbline Advisers raised its holdings in Minerva Neurosciences by 35.9% in the 2nd quarter. Rhumbline Advisers now owns 27,082 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 7,150 shares during the period. 69.29% of the stock is currently owned by institutional investors.

Minerva Neurosciences, Inc (NASDAQ NERV) traded down 2.68% during midday trading on Friday, hitting $7.25. The stock had a trading volume of 89,196 shares. The stock has a 50-day moving average price of $7.09 and a 200 day moving average price of $7.66. The firm’s market cap is $308.19 million. Minerva Neurosciences, Inc has a one year low of $5.55 and a one year high of $14.15.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.07. During the same period in the prior year, the business earned ($0.18) earnings per share. On average, analysts predict that Minerva Neurosciences, Inc will post ($0.90) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Nexthera Capital LP Lowers Holdings in Minerva Neurosciences, Inc (NASDAQ:NERV)” was originally published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at http://www.mareainformativa.com/nexthera-capital-lp-has-5-09-million-holdings-in-minerva-neurosciences-inc-nerv/117606/.

A number of analysts have issued reports on NERV shares. BidaskClub downgraded Minerva Neurosciences from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Zacks Investment Research raised Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research report on Wednesday, August 9th. Finally, Citigroup Inc. assumed coverage on Minerva Neurosciences in a report on Friday, September 1st. They issued a “buy” rating and a $11.00 price target for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $13.94.

Minerva Neurosciences Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Stock Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related stocks with our FREE daily email newsletter.